Rhythm Pharmaceuticals

Also NDA Bardet-Biedl syndrome, Alstrom syndrome, Clin3 multiple types genetic obesity, Clin3 pediatric obesity, 3 trials Clin2 multiple obesity types, weekly formulation 2 trials Clin2/Clin3 obesity

Rhythm Pharmaceuticals is developing drugs that target the leptin-melanocortin signaling pathway to treat patients with obesity. Obesity is the result of many factors that disrupt energy balance, not just due to food consumption. Mutations in the melanocortin-4 receptor (MC4R) pathway are linked with hyperphagia and severe obesity. With the help of their DNA database focused on obesity, Rhythm is mapping the MC4R signaling pathway to understand the functional and clinical relevance of genetic variants to identify effective drug targets. Rhythm has already completed two Phase 3 clinical trials using setmelanotide.